AUPO108596A0 - Treatment of obesity - Google Patents

Treatment of obesity

Info

Publication number
AUPO108596A0
AUPO108596A0 AUPO1085A AUPO108596A AUPO108596A0 AU PO108596 A0 AUPO108596 A0 AU PO108596A0 AU PO1085 A AUPO1085 A AU PO1085A AU PO108596 A AUPO108596 A AU PO108596A AU PO108596 A0 AUPO108596 A0 AU PO108596A0
Authority
AU
Australia
Prior art keywords
obesity
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPO1085A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Diabetes Institute
Original Assignee
International Diabetes Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Diabetes Institute filed Critical International Diabetes Institute
Priority to AUPO1085A priority Critical patent/AUPO108596A0/en
Publication of AUPO108596A0 publication Critical patent/AUPO108596A0/en
Priority to ZA976333A priority patent/ZA976333B/en
Priority to PCT/AU1997/000453 priority patent/WO1998003175A1/en
Priority to AU34296/97A priority patent/AU3429697A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AUPO1085A 1996-07-18 1996-07-18 Treatment of obesity Abandoned AUPO108596A0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AUPO1085A AUPO108596A0 (en) 1996-07-18 1996-07-18 Treatment of obesity
ZA976333A ZA976333B (en) 1996-07-18 1997-07-17 Treatment of obesity
PCT/AU1997/000453 WO1998003175A1 (en) 1996-07-18 1997-07-18 Treatment of obesity
AU34296/97A AU3429697A (en) 1996-07-18 1997-07-18 Treatment of obesity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO1085A AUPO108596A0 (en) 1996-07-18 1996-07-18 Treatment of obesity

Publications (1)

Publication Number Publication Date
AUPO108596A0 true AUPO108596A0 (en) 1996-08-08

Family

ID=3795401

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPO1085A Abandoned AUPO108596A0 (en) 1996-07-18 1996-07-18 Treatment of obesity

Country Status (3)

Country Link
AU (1) AUPO108596A0 (en)
WO (1) WO1998003175A1 (en)
ZA (1) ZA976333B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7627920B2 (en) 2006-06-09 2009-12-08 Whirlpool Corporation Method of operating a washing machine using steam
US7591859B2 (en) 2006-08-15 2009-09-22 Whirlpool Corporation Water supply control for a steam generator of a fabric treatment appliance using a weight sensor
US8393183B2 (en) 2007-05-07 2013-03-12 Whirlpool Corporation Fabric treatment appliance control panel and associated steam operations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3438284A1 (en) * 1984-10-16 1985-03-07 Hans-Harald von 2400 Lübeck Tilly Nicotine-containing depot plaster
DE3639418A1 (en) * 1986-11-18 1988-06-09 Forschungsgesellschaft Rauchen NICOTINE-BASED AGENT
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US5573774A (en) * 1993-02-02 1996-11-12 Keenan; Robert M. Nicotine metabolites, nicotine dependence and human body weight
WO1996000072A1 (en) * 1994-06-23 1996-01-04 The Procter & Gamble Company Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine
MA23588A1 (en) * 1994-06-23 1995-12-31 Procter & Gamble TREATMENT OF NEED FOR NICOTINE AND / OR SMOKING-RELATED SYNDROME
AU2702795A (en) * 1994-06-23 1996-01-19 Procter & Gamble Company, The Treatment of nicotine craving and/or smoking withdrawal symptoms with a solid or semi-solid composition containing nicotine and caffeine or xanthine, especially for nasal administration
MA23587A1 (en) * 1994-06-23 1995-12-31 Procter & Gamble TREATMENT OF NEED FOR NICOTINE AND / OR SMOKING-RELATED SYNDROME

Also Published As

Publication number Publication date
WO1998003175A1 (en) 1998-01-29
ZA976333B (en) 1998-07-23

Similar Documents

Publication Publication Date Title
AU7772794A (en) Treatment of obesity
AU5901896A (en) Use of aryl-substituted cyclobutylalkylamines for treating obesity
AUPM761094A0 (en) Treatment of hides
AU1251197A (en) Treatment of liquors
AU3552697A (en) Novel treatment of leptine resistance
AU2870597A (en) Treatment of liquid
AU1926597A (en) Treatment of cocoa
AU4546096A (en) Treatment of waste
AU4027097A (en) Method of treatment
AUPO108596A0 (en) Treatment of obesity
AUPN808296A0 (en) Bauxite treatment
AU3429697A (en) Treatment of obesity
AU7545998A (en) Treatment of osteoporosis
AU4310397A (en) Treatment of waste
HK1026915A (en) Treatment of obesity
AUPP039897A0 (en) Treatment of obesity
AU2002301576A1 (en) Treatment of obesity
AUPO900197A0 (en) Treatment of obesity
AU696976B2 (en) Effluent treatment
AU6112299A (en) Treatment of effluents
AU8557598A (en) Treatment of fluids
AU4124497A (en) Treatment of diabetes
AU3247995A (en) Treatment of hides
AU2375297A (en) Treatment of hides
AUPO598197A0 (en) Treatment of hides